



Keenan[®]

Keenan Pharmacy Services
San Joaquin Valley Insurance Authority
(SJVIA)
Consultants Report: Q1 2024

SJVIA- EmpiRx Health – Q1 2024 Highlights

- SJVIA's total plan cost increased in Q1 2024 by 8% to \$6,926,258
 - Tulare: \$2,910,547 in Plan Cost
 - Fresno: \$4,015,711 in Plan Cost
 - The increase in plan spend can be attributed to an increase in Total Rx count.
- Specialty claims plan cost decreased in Q1 2024
 - Q1 2024 \$2,608,106 (Q1 2023 - \$2,958,253)
 - Tulare: \$1,123,536
 - Fresno: \$1,484,570
 - 685 Scripts filled in Q1 2024 (Q1 2023 – 705)
 - Tulare: 243
 - Fresno: 442
- Variable Copay Assistance (VCAP) Savings (May 1, 2023 – April 30, 2024)
 - SJVIA Total Savings \$1,237,715
 - Tulare: \$460,571
 - Fresno: \$777,144
- Rebates:
 - Q1-2024 net rebate amount is \$1,235,855
- Clinical Savings: 2023: \$5,781,245
 - SJVIA Tulare: Jan-Dec 2023, \$2,321,344
 - SJVIA Fresno: Jan-Dec 2023, \$3,459,901

KPS Audit

KPS conducts a yearly financial audit of EmpiRx clinical savings, Average Wholesale Price (AWP) discounts and rebate performance against the client's aggregate contractual guarantees.



Top Clinical Cost Drivers by Drug (Q1 2024)

- OZEMPIC (ANTI-DIABETICS)
 - 2024 ingredient costs: \$671,160.59
 - 277 Utilizers
- WEGOVY (ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS)
 - 2024 ingredient costs: \$362,584.02
 - 136 Utilizers
- HUMIRA PEN (ANALGESICS - ANTI-INFLAMMATORY)
 - 2024 ingredient costs: \$291,331.60
 - 17 Utilizers
- DUPIXENT (DERMATOLOGICALS)
 - 2024 ingredient costs: \$260,715.93
 - 26 Utilizers
- MOUNJARO (ANTI-DIABETICS)
 - 2024 ingredient costs: \$253,017.96
 - 112 Utilizers
- JARDIANCE (ANTI-DIABETICS)
 - 2024 ingredient costs: \$200,013.30
 - 120 Utilizers
- TREMFYA (DERMATOLOGICALS)
 - 2024 ingredient costs: \$179,680.56
 - 9 Utilizers
- FARXIGA (ANTI-DIABETICS)
 - 2024 ingredient costs: \$122,551.81
 - 74 Utilizers
- EMPAVELI (HEMATOLOGICAL AGENTS - MISC)
 - 2024 ingredient costs: \$117,630.81
 - 1 Utilizers
- TRULICITY (ANTI-DIABETICS)
 - 2024 ingredient costs: \$113,011.67
 - 67 Utilizers
- Note: Specialty medications require a prior authorization before they can be filled.



New Medications Available in the Market

- **Update on Zepbound**

- In June Zepbound manufacture Eli Lilly applied for U.S. regulatory approval to expand the use of its weight-loss drug Zepbound to include treatment of sleep apnea.
- Eli Lilly is expecting regulators to make a decision as early as the end of the year.
 - Zepbound for obstructive sleep apnea could be launched at the beginning of 2025
- EmpiRx will be looking to see if we can identify potential impact/usage based on current medication usage for a diagnosis of obstructive sleep apnea.

- **New Drug Approved**

- **Kisunla (donanemab):** Second medication approved for treatment of mild cognitive impairment or early Alzheimer's disease (AD).
- Kisunla works by targeting amyloid in the brain, considered a hallmark of Alzheimer's disease.
 - An estimated 6.7 million people in the U.S. ages 65 and older were living with Alzheimer's last year, according to the Alzheimer's Association. The number is projected to increase to 13.8 million by 2060.
- Administered as a 350-mg/20-mL intravenous infusion once per month, Kisunla's treatment population includes those with mild cognitive impairment, as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.
 - Pricing of Kisunla at \$695.65 per vial, which comes to about \$12,522 for a six-month treatment period, \$32,000 for one year of treatment or \$48,696 for 18 months.
 - In comparison, Leqembi's wholesale acquisition cost is an estimated \$26,500 per year, based on 10-mg/kg biweekly doses
 - Currently, SJVIA excludes medications that are administered Intravenously on the pharmacy side.

